SpringerProtocols: Abstract: Screening of Novel Inhibitors of HIV-1 Reverse Transcriptase with a Reporter Ribozyme Assay

11. Screening of Novel Inhibitors of HIV-1 Reverse Transcriptase with a Reporter Ribozyme Assay

By: Satoko Yamazaki², Michael Famulok²

Abstract

Full Text

Download PDF (394K)

“Highly active anti-retroviral therapy (HAART)” is currently the standard treatment for human immunodeficiency virus (HIV). This treatment consists of a cocktail of two reverse transcriptase (RT) inhibitors and a protease inhibitor. Despite the success of this regimen, there is a continuing need for innovative drug to overcome problems with tolerability and the emergence of viral resistance. The present protocol describes a novel strategy to rapidly screening a new class of small molecule HIV-1 RT inhibitors, which bind to the primer/template binding site of RT, as yet an unexplored site for small molecule interference on this target. The assay is based on aptamer-displacement which is visualized by applying a rationally designed HIV-1 RT responsive ribozyme. The handiness of the assay procedure permits automation, compatible with high-throughput screening (HTS). Subsequently, the identified hit compounds have been evaluated by an in vitro enzymatic assay to test the inhibitory potential. The strategy provides a powerful and efficient screening format for site-directed inhibitors with biological activity.

Affiliation(s): (2) Life and Medical Sciences, Program Unit Chemical Biology and Medicinal Chemistry, University of Bonn, Bonn, Germany

Book Title: Nucleic Acid and Peptide Aptamers: Methods and Protocols

Series: Methods in Molecular Biology | Volume: 535 | Pub. Date: Mar-03-2009 | Page Range: 1-13 | DOI: 10.1007/978-1-59745-557-2_11

Subject: Cell Biology

Key Words: HTS - aptamer - allosteric ribozyme - reporter ribozyme - HIV-1 RT - FRET

References

Download References

1.	Hartig, J.S. and Famulok, M. (2002) Reporter ribozymes for real-time analysis of domain-specific interactions in biomolecules: HIV-1 reverse transcriptase and the primer-template complex. Angew. Chem. Int. Ed. Engl. 41, 4263–4266.

2.	Tuerk, C., MacDougal, S. and Gold, L. (1992) RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase Proc. Natl. Acad. Sci. U.S.A. 89, 6988–6992.

3.	Jaeger, J., Restle, T. and Steitz, T.A. (1998) The structure of HIV-1 reverse transcriptase complexed with an RNA pseudoknot inhibitor. EMBO J. 17, 4535–4542.

4.	Chaloin, L., Lehmann, M.J., Sczakiel, G. and Restle, T. (2002) Endogenous expression of a high-affinity pseudoknot RNA aptamer suppresses replication of HIV-1. Nucleic Acids Res. 30, 4001–4008.

5.	Joshi, P. and Prasad, V.R. (2002) Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment). J. Virol. 76, 6545–6557.

6.	Jonckheere, H., Anne, J. and De Clercq, E. (2000) The HIV-1 reverse transcription (RT) process as target for RT inhibitors. Med. Res. Rev. 20, 129–154.

7.	Menendez-Arias, L. (2002) Targeting HIV: antiretroviral therapy and development of drug resistance Trends Pharmacol. Sci. 23, 381–388.

8.	Imamichi, T. (2004) Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors. Curr. Pharm. Des. 10, 4039–4053.

9.	Joshi, P.J., Fisher, T.S. and Prasad, V.R. (2003) Anti-HIV inhibitors based on nucleic acids: emergence of aptamers as potent antivirals. Curr. Drug Targets Infect. Disord. 3, 383–400.

10.	Ng, E.W., Shima, D.T., Calias, P., Cunningham, E.T., Jr., Guyer, D.R. and Adamis, A.P. (2006) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease Nat. Rev. Drug Discov. 5, 123–132.

11.	Hartig, J.S., Najafi-Shoushtari, S.H., Grüne, I., Yan, A., Ellington, A.D. and Famulok, M. (2002) Protein-dependent ribozymes report molecular interactions in real time. Nat. Biotechnol. 20, 717–722.

12.	Yamazaki, S., Tan, L., Mayer, G., Hartig, J.S., Song, J.N., Reuter, S., Restle, T., Laufer, S.D., Grohmann, D., Kräusslich, H.G., Bajorath, J. and Famulok, M. (2007) Aptamer displacement identifies alternative small-molecule target sites that escape viral resistance. Chem. Biol. 14, 804–812.

13.	Nimjee, S.M., Rusconi, C.P. and Sullenger, B.A. (2005) Aptamers: an emerging class of therapeutics. Annu. Rev. Med. 56, 555–583.

14.	Que-Gewirth, N.S. and Sullenger, B.A. (2007) Gene therapy progress and prospects: RNA aptamers. Gene Ther. 14, 283–291.

Comments (Loading...)

Post comment/View all comments